May 21, 2018 5:21 PM ET


Company Overview of Kowa Pharmaceuticals America, Inc.

Company Overview

Kowa Pharmaceuticals America, Inc., a specialty pharmaceutical company, engages in the acquisition, development, licensing, and marketing of pharmaceutical products. The company focuses on cardiometabolic therapeutics. It offers LIVALO, which is an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B (Apo B), and triglycerides; and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. The company also provides LIPOFEN (fenofibrate capsules), which is indicated as an adjunctive therapy to diet to reduce elevated triglycerides and to increase high density lipoprotein cholesterol in adult patients...

530 Industrial Park Boulevard

Montgomery, AL 36117

United States

Founded in 2001





Key Executives for Kowa Pharmaceuticals America, Inc.

Chairman, Chief Executive Officer and President
Age: 55
Chief Financial Officer
Vice President of Trade and Business Development
Vice President of Medical Affairs
Vice President of Sales
Compensation as of Fiscal Year 2017.

Kowa Pharmaceuticals America, Inc. Key Developments

Kowa Pharmaceuticals America Inc. Wins $104.43 Million Federal Contract

Kowa Pharmaceuticals America Inc. won a $104,434,809 federal contract from the U.S. Department of Veterans Affairs National Acquisition Center for medical, dental and veterinary equipment and supplies.

Kowa Pharmaceuticals America, Inc. Announces INTREPID Trial Results in the Lancet HIV

Kowa Pharmaceuticals America, Inc. announced publication of results of the INTREPID Trial (HIV-infected patients and treatment with pitavastatin vs. pravastatin for Dyslipidemia) in The Lancet HIV. Results of the Phase 4 trial showed that LIVALO (pitavastatin) 4 mg was superior to pravastatin 40 mg in reducing LDL cholesterol (LDL-C) in adults with HIV and dyslipidemia and had a comparable safety profile. Dyslipidemia affects more than three-fourths of people with HIV, putting them at significantly increased risk for cardiovascular disease. However, treatment of elevated LDL cholesterol in this patient population is challenging because of drug interactions between statins and commonly used antiretroviral agents. The finding that LIVALO was more effective than pravastatin in lowering LDL cholesterol and was well tolerated in HIV patients with dyslipidemia suggests it could be a viable treatment option for managing dyslipidemia and contributing factors in adults with HIV. The INTREPID trial is the first to evaluate the efficacy and safety of LIVALO in this difficult-to-treat patient population. The results not only demonstrate that LIVALO is superior to pravastatin in lowering LDL cholesterol, but also in maintaining moderate-intensity LDL cholesterol reduction similar to the non-HIV infected adult population. Furthermore, LIVALO can be used in patients receiving complex antiretroviral therapy at the high dose of LIVALO because it is not mainly metabolized via the cytochrome P450 enzyme system. The prospective, randomized, double-blind, active-controlled, Phase 4 superiority trial enrolled adults with HIV (CD4 cell counts >200 cells/mm3 and HIV-1 RNA.

Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. Announces Settlement of Patent Litigation with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd

Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. announced that they have finalized as agreement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. To settle all outstanding patent litigation related to Livalo (potavastatin calcium) tablets. Under the terms of the agreement, Kowa and Nissan grants Zydus a license to Zydus’ generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Kowa Pharmaceuticals America, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at